ImmunoGen Inc (IMGN) is a small-cap biotech stock. Biotech stocks can be particularly hard to analyze, often having negative earnings and historically posting losses, before eventually becoming profitable businesses. Success and also failures often hinge on one key drug or product. Therefore understanding the drug(s) the company is developing, or have developed, and determining the likelihood of it being brought to market is key. Forecasting revenues such a product/drug could generate as well as assessing future pipeline products helps provide an overall valuation and growth forecast. The following analysis indentifies the game changing nature of IMG's biotechnology in the ongoing battle against cancer and shows with conservative forecasts that IMGN offers significant capital upside.
Only subscribers can access this article, which is part of the PRO research library covering 3,578 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: